[{"id":"96478ee8-ea1d-46f0-9076-86b0a0a5b146","acronym":"","url":"https://clinicaltrials.gov/study/NCT02869217","created_at":"2021-02-16T02:53:03.033Z","updated_at":"2024-07-02T16:35:26.728Z","phase":"Phase 1","brief_title":"Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors","source_id_and_acronym":"NCT02869217","lead_sponsor":"University Health Network, Toronto","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-08"},{"id":"2af4501d-3698-4fa1-bef4-a73d1a7b2ae3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250325","created_at":"2021-02-16T02:53:12.531Z","updated_at":"2024-07-02T16:35:26.928Z","phase":"Phase 1/2","brief_title":"Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma","source_id_and_acronym":"NCT03250325","lead_sponsor":"Takara Bio Inc.","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 01/23/2020","primary_completion_date":" 01/23/2020","study_txt":" Completion: 03/09/2022","study_completion_date":" 03/09/2022","last_update_posted":"2023-12-06"},{"id":"bc490f3e-ae39-4b4d-8c5b-7cc4684c6d84","acronym":"","url":"https://clinicaltrials.gov/study/NCT02366546","created_at":"2021-02-16T02:52:35.194Z","updated_at":"2024-07-02T16:37:05.826Z","phase":"Phase 1","brief_title":"Investigator Initiated Phase 1 Study of TBI-1301","source_id_and_acronym":"NCT02366546","lead_sponsor":"Mie University","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 9","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":"","study_completion_date":"","last_update_posted":"2018-10-24"}]